![](https://i.imgur.com/CLvY2jA.png")
07-03-2022, 06:36 PM
Chile
CoronaVac® is safe and immunogenic in subjects aged 3-17 years old and is thus likely to confer protection against infection caused by SARS-CoV-2 variants in this target population.
https://www.medrxiv.org/content/10.1101/...in%20Chile.
CoronaVac® is safe and immunogenic in subjects aged 3-17 years old and is thus likely to confer protection against infection caused by SARS-CoV-2 variants in this target population.
https://www.medrxiv.org/content/10.1101/...in%20Chile.
